Skip to main content
main-content

01.12.2017 | Research | Ausgabe 1/2017 Open Access

Journal of Hematology & Oncology 1/2017

A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia

Zeitschrift:
Journal of Hematology & Oncology > Ausgabe 1/2017
Autoren:
Simona Piemontese, F. Ciceri, M. Labopin, W. Arcese, S. Kyrcz-Krzemien, S. Santarone, H. Huang, D. Beelen, N. C. Gorin, C. Craddock, Z. Gulbas, A. Bacigalupo, M. Mohty, A. Nagler, on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s13045-017-0394-2) contains supplementary material, which is available to authorized users.
Abbreviations
AL
Acute leukemia
ALL
Acute lymphoblastic leukemia
AML
Acute myeloid leukemia
ATG
Anti-thymocyte globulin
ATT
Average treatment effect among the treated
BM
Bone marrow
CB
Cord blood
CMV
Cytomegalovirus
CR
Complete remission
GRFS
Graft-versus-host relapse-free survival
GVHD
Graft-versus-host disease (acute aGvHD or chronic cGvHD)
HAPLO
Haploidentical donor
LFS
Leukemia-free survival
MAC
Myeloablative conditioning regimen
MMUD
Mismatched unrelated donor
MRD
Matched related donor
MUD
Matched unrelated donor
NRM
Non-relapse mortality
OS
Overall survival
PB
Peripheral blood
PMN
Polymorphonuclear cells
PS
Propensity score
PT-Cy
Post-transplant cyclophosphamide
RI
Relapse incidence
RIC
Reduced intensity conditioning regimen
SC
Stem cell
SCT
Stem cells transplantation
TX
Transplant

Background

Allogeneic stem cell transplantation (allo-SCT) represents the only possible cure for most adult acute leukemias (AL). HLA-matched related (MRD) or unrelated donors (MUD) are usually considered the preferable donors, but they are not available for all the patients with an indication for allo-SCT. In the absence of a HLA-matched donor, allo-SCT from mismatched unrelated donors (MMUD), cord blood units (CB), or haploidentical (Haplo) donors are potential alternatives.
A Haplo donor is available for virtually all AL patients, enabling minimal delay and access to repeated stem cell (SC) donations or donor lymphocyte infusions, if needed. These are the main reasons for the increasing numbers of Haplo-SCT for AL in recent years. Unmanipulated (non ex vivo T-depleted) grafts from Haplo donors, in comparison to T-depleted ones, result in lower incidence of serious infections due to faster immune reconstitution and stronger graft versus leukemia effect [ 1, 2]. In addition, the introduction of more effective regimens for graft-versus-host disease (GvHD) prophylaxis for T-replete Haplo-SCT contributed to reduce GvHD incidence and to increase the use of unmaniplated grafts for the Haplo setting [ 310].
Recently, several reports have shown comparable allo-SCT outcomes between Haplo and historical MRD, MUD, and MMUD series [ 1115]. However, these are mostly but one [ 14] single center studies with limited number of patients [ 11, 12, 15] in various disease categories and status. For these reasons, we decided to perform a large, registry-based study, using the European Society of Bone Marrow Transplantation (EBMT)-Acute Leukemia Working Party (ALWP) registry, comparing T-replete Haplo-SCT to transplants from MUD and MMUD for AL patients in first or second remission.

Methods

In order to be included in the study, the patients had to fulfill all the following criteria: age ≥18 years; de novo AL; disease status at transplant: complete remission 1 (CR1) or 2 (CR2); family donor with host/donor number of HLA mismatches ≥2 (Haplo), or MUD 10/10 or MMUD 9/10 (patients and donors should have HLA A, B, C, and DRB1 and DQB1 allelic typing performed); peripheral blood (PB) or bone marrow (BM) or both as source of SC; no ex vivo T cell depletion; and first allo-SCT (previous autologous SCT was allowed). All patients underwent transplantation between January 2007 and December 2013. We were able to verify the inclusion criteria for 265 Haplo-SCT, 2490 MUD 10/10-SCT, and 813 MMUD 9/10-SCT. This was a retrospective multicenter analysis. Data were provided and approved for this study by the ALWP of the EBMT group registry. The EBMT is a non-profit, scientific society representing more than 600 transplant centers mainly in Europe. The EBMT promotes all activity aiming to improve stem cell transplantation or cellular therapy, which includes registering all the activity relating to stem cell transplants. Data are entered, managed, and maintained in a central database with internet access; each EBMT center is represented in this database. There are no restrictions on centers for reporting data, except for those required by the law on patient consent, data confidentiality, and accuracy. Quality control measures included several independent systems: confirmation of validity of the entered data by the reporting team, selective comparison of the survey data with minimum essential data A (MED-A) data sets in the EBMT registry database, cross-checking with the National Registries, and regular in-house and external data audits. Since 1990, patients have provided informed consent authorizing the use of their personal information for research purposes.

Definitions and statistical analysis

The primary endpoints were leukemia-free survival (LFS) and overall survival (OS). The secondary endpoints were engraftment, acute and chronic GVHD (aGVHD and cGVHD), relapse incidence (RI), non-relapse mortality (NRM), and graft-versus-host relapse-free survival (GRFS) [ 16]. LFS was defined as time to death or relapse, whichever came first. OS was defined as time to death from all causes. NRM was defined as death without evidence of relapse. Engraftment was defined as the first of three consecutive days with an absolute neutrophil count > 0.5 × 10 9/L. Acute GVHD was graded according to the modified Seattle-Glucksberg criteria [ 17] and cGVHD according to the revised Seattle criteria [ 18].
We used propensity scores (PS) weighting to control for pre-treatment imbalances on observed variables. The following factors were included in the PS model: patient age, time from diagnosis to transplantation, year of transplant, diagnosis (AML versus ALL), status at transplant (CR1 versus CR2), cytogenetics group, donor/patient CMV serology, conditioning (RIC versus MAC), and sex matching (female donor to male recipient versus other). The estimation of propensity score was performed using generalized boosted models [ 19].
As the study question was whether Haplo could replace 10/10 or 9/10 MUD, we weighted the groups receiving either MUD 10/10- and MMUD 9/10-HSCT to match the characteristics of patients receiving Haplo-SCT, by estimating the average treatment effect among the treated (ATT); Haplo-HSCT being the treated group. The ATT weights equal one for Haplo-HSCT, and it equals the ratio of the propensity score to one minus the propensity score in the two UD-HSCT groups. Therefore, UD patients that were significantly different from average haplo-grafted patients had a low contribution in the comparisons. We checked the balance between the groups looking to ATT weighted means. Then, we used pairwise ATTs to fit the weighted Kaplan-Meier and Cox models separately for Haplo- versus MUD 10/10-HSCT and Haplo- versus MMUD 9/10-HSCT.
The type I error rate was fixed at 0.05 for determination of factors associated with time to event. Analyses were performed using the R statistical software version 3.2.3 (R Development Core Team, Vienna, Austria); propensity score analysis was performed using the mnps function of the Twang package and weighted analyses using the survey package [ 20].

Results

Patients’ and donors’ characteristics

Patient’s and host/donors’ characteristics are showed in Table  1. Regimens, stem cell source, and GvHD prophylaxis are described in Table  2. Anti-thymocyte globulin (ATG) was used for in vivo T cell depletion in 120/265 Haplo (45%), 1457/2490 (59%) 10/10 MUD, and 550/813 (82%) 9/10 MMUD. Campath was used in 6/265 Haplo (1%), 302/2490 (12%) MUD, and 124/813 (18%) MMUD. PT-Cy was used in 107/265 Haplo (40%), 27/2490 (1%) MUD, and 12/813 (1%) MMUD. Among patients receiving a MMUD 9/10, 204 (25%) were mismatched in locus A, 115 (14%) in locus B, 275 (34%) in locus C, 62 (8%) in locus DRB1, and 157 (19%) in locus DQB1. Allelic typing for locus A, B, C, DRB1, and DQB1 was available for all patients and donors.
Table 1
Patients’ and host/donor characteristics
 
Haplo
MUD10/10
MMUD 9/10
MUD 10/10 vs Haplo
MMUD 9/10 vs Haplo
No.
265
2490
813
   
Follow-up
34.2 (3–84)
35.7 (1–103)
35.8 (1–102)
0.93
0.72
Age
42.8 (18–75)
47.0 (18–76)
44.8 (18–71)
<10–3
0.017
Year of Tx
2011 (07–13)
2010 (07–13)
2010 (07–13)
<10–3
<10–3
Diagnosis to transplant
260 days (82–5784)
196 days (71–5793)
223d (73–4452)
<10–3
0.016
Diagnosis
 AML
176
1645
510
   
66%
66%
63%
   
 ALL
89
845
303
0.90
0.28
34%
34%
37%
   
Disease status
 CR1
159
1901
580
   
60%
76%
71%
   
 CR2
106
589
233
<10–3
0.001
40%
24%
29%
   
Patient sex
 Male
155
1344
442
   
58%
54%
54%
   
 Female
110
1146
371
0.16
0.24
42%
46%
46%
   
Donor sex
 Male
139
1782
490
   
52%
72%
61%
   
 Female
126
690
312
<10–3
0.013
48%
28%
39%
   
Female to male
 No
191
2186
659
   
72%
88%
82%
   
 Yes
74
286
143
<10–3
<10–3
28%
12%
18%
   
CMV neg to neg
 No
225
1673
577
   
86%
69%
73%
   
 Yes
36
754
212
<10–3
<10–3
14%
31%
27%
   
Cytogenetics
 Good
29
261
68
   
11%
10%
8%
   
 Intermediate
168
1398
446
   
63%
56%
55%
   
 Poor
68
831
299
0.04
0.004
26%
33%
37%
   
See text for abbreviations. Cytogenetic risk at diagnosis for AML: good t(8;21), inv16 or t(16;16); poor monosomy/deletion 5 or 7, abnormalities 11q23, complex karyotype (≥3 abnormalities); intermediate all the others. Cytogenetic risk at diagnosis for ALL: adverse t(9;22) or t(4;11), intermediate all the others
Table 2
Conditioning regimens, stem cell source, and in vivo T cell depletion
No.
Haplo
MUD10/10
MMUD 9/10
MUD 10/10 vs Haplo
MMUD 9/10 vs Haplo
265
2490
813
   
Conditioning
 MAC
138
1460
489
   
52%
59%
60%
   
 RIC
127
1018
322
0.03
0.02
48%
41%
40%
   
Stem cell source
 BM
141
473
141
<10–4
<10–4
53%
19%
17%
   
 PB
124
2017
672
   
47%
81%
83%
   
In vivo T cell depletion
 No
38
720
137
<10–4
<10–4
15%
29%
17%
   
 ATG
120
1743
664
   
45%
70%
82%
   
 Pt-Cy
107
27
12
   
40%
1%
1%
   
See text for abbreviations

Engraftment

The 30-day CI of engraftment was 95% (92–97%) for Haplo, 97% (93–98%) for MUD 10/10, and 92% (88–95%) for MMUD 9/10. In weighted Cox model, CI of engraftment resulted to be lower in Haplo versus MUD 10/10 ( p = 0.015) but not different between Haplo and MMUD 9/10 ( p = 0.62).

Non-relapse mortality, acute and chronic GvHD

The weighted CI of NRM at 3 years was 29% (23–34%), 21% (15–26%), and 29% (23–35%) for Haplo , MUD 10/10, and MMUD 9/10 (Fig.  1a), respectively. In weighted Cox model, NRM was lower in MUD 10/10 as compared in Haplo, but not different from that in MMUD 9/10 (Table 3). The percentage of grades II–IV aGvHD was 28% (22–33%), 25% (18–31%), and 27% (21–33%) for Haplo, MUD 10/10, and MMUD 9/10, respectively. The frequency of grades III–IV aGvHD was 10% (6–13%) for Haplo, 7% (3–10%) for MUD 10/10, and 11% (6–15%) for MMUD 9/10. The 3-year CI of overall cGvHD and extensive cGvHD was 34% (28–40%) and 15% (10–20%), 40% (33–47%) and 22% (15–28%), and 33% (26–39%) and 18% (12–23%) for Haplo, MUD 10/10, and MMUD 9/10, respectively. Neither grades II–IV aGvHD nor chronic GvHD incidences differed between Haplo versus MUD 10/10 and Haplo versus MMUD 9/10 in weighted Cox analysis (Table  3).
Table 3
Weighted Cox model for NRM, RI, LFS, OS, and GRFS
3-year
MUD 10/10 vs Haplo
p
MMUD 9/10 vs Haplo
p
HR (95%CI)
HR (95%CI)
Day 30 PMN engraftment
0.845 (0.740-0.968)
0.015
0.961 (0.819-1.127)
0.623
II–IV aGvHD
0.8877 (0.6777–1.163)
0.387
1.0433 (0.7716–1.411)
0.783
III–IV aGvHD
0.673 (0.4334–1.045)
0.078
1.184 (0.7221–1.942)
0.5027
cGVHD all
1.0763 (0.8474–1.367)
0.547
0.9555 (0.7264–1.257)
0.745
Extensive cGvHD
1.483 (0.9890–2.224)
0.057
1.288 (0.8342–1.990)
0.253
NRM
0.6363 (0.4838–0.8369)
0.0012
0.9905 (0.7009–1.3997)
0.957
RI
0.8624 (0.6668–1.115)
0.259
0.8426 (0.6312–1.125)
0.245
LFS
0.7487 (0.6229–0.8998)
0.002
0.9164 (0.7296–1.1511)
0.45
OS
0.7074 (0.5824–0.8591)
0.0005
0.9300 (0.7302–1.1844)
0.56
GRFS
0.8804 (0.7433–1.043)
0.14
1.0313 (0.8370–1.271)
0.772
See text for abbreviations

Relapse incidence

The weighted CI of relapse at 3 years was 30% (24–35%), 29% (22–35%), and 25% (19–31%) for Haplo, MUD 10/10, and MMUD 9/10, respectively (Fig.  1b).The type of donor was not a predictive factor for relapse in weighted Cox model (Table  3).

LFS, OS, and GRFS

The median follow-up among survivors was 34 (range, 3–84) months for Haplo, 36 (range, 1–103) for MUD 10/10, and 36 (range, 1–102) for MMUD 9/10, respectively. The weighted probability of LFS at 3 years was 41% (35–48%), 50% (43–58%), and 46% (39–53%) for Haplo, 10/10 MUD, and 9/10 MMUD, respectively (Fig.  2).The weighted probability of 3-year OS was 46% (40–53%), 56% (49–64%), and 48% (41–56%) (Fig.  2).The 3-year GRFS was 33% (28–40%), 36% (29–44%), and 34% (28–41%) for Haplo, 10/10 MUD, and 9/10 MMUD, respectively (Fig. 2). In the weighted Cox analysis, LFS and OS resulted to be better for MUD 10/10 compared with Haplo, but no statistical difference comparing Haplo with MUD 9/10. No statistical differences were found in GRFS according to the type of donor in the weighted Cox analysis (Table  3).

Discussion

In the absence of a MRD for allo-SCT in acute leukemia, the ideal donor still remains to be determined. The current report represents a large registry study comparing the outcome between transplants from Haplo and MUD 10/10 or MMUD 9/10 for adult patients with de novo AL in remission.
As a recent ALWP-EBMT survey on unmanipulated haploidentical transplantation in AL showed a lower incidence of aGvHD in patients receiving PT-Cy but no significant statistical differences in either LFS or OS [ 21], in our study we included all the non T-depleted Haplo-SCT registered in the EBMT database.
Previous reports described worse outcomes after MMUD in comparison to MUD [ 2226], and this finding was in accordance to our preliminary data and to a recent ALWP publication [ 27].
We did not find any differences in terms of LSF and OS in the 813 MMUD-SCT according to HLA-DQ mismatch in univariate analysis ( p = 0.35). Therefore, we decided to compare separately MUD 10/10 and MMUD 9/10 transplants with Haplo.
The 30-day CI of engraftment proved to be lower in Haplo than in MUD 10/10 but not different between Haplo and MMUD 9/10. In addition to the type of donor, the number and type of chemotherapy cycles pre-transplant and/or early post-transplant infections, in particular viral, could have had an impact on differences in engraftment. A lower incidence of engraftment in Haplo compared in UD was previously reported in both reduced intensity [ 14] and myeloablative conditioning transplants [ 15].
Notably, we did not find any difference in the incidence of either aGvHD  > II or cGvHD according to donor type in line with similar comparisons in literature. This was true also for grades III–IV aGvHD and extensive cGvHD. In the recent report comparing Haplo using PT-Cy to UD from the Center for International Blood and Marrow Transplant Research (CIBMTR), the authors describe a lower incidence of acute and cGvHD in Haplo on univariate analysis [ 14], but most of the Haplo were performed using BM as stem cell source, and most of the UD using PB without receiving any in vivo T cell depletion. Of note, they did not find any difference in the 3-year cGvHD incidence according to donor type when analyzing only patients receiving BM. The role of stem cell source as risk factor for cGvHD after Haplo-SCT remains to be determined. While some reports do not show any difference in terms of cGvHD between PB and BM in haploidentical transplantations using PT-Cy [ 28, 29], a recent comparison from CIBMTR concludes for a high incidence of cGvHD using PB instead of BM [ 30]. Notable, in the context of UD, cGvHD has been shown to be higher using PBSC [ 31] especially if not using in vivo T cell depletion [ 32].
The 3-year NRM was higher using Haplo (29%) compared with MUD 10/10 (21%) but identical compared with MMUD (29%), in contrast with other reports on similar comparisons where the authors did not find any difference [ 1115]. This higher NRM in Haplo compared in MUD 10/10 could be in part due to the use of in vivo T cell depletion other than PT-Cy in the 45% of our Haplo [ 33]. In addition to the type of in vivo T cell depletion, also, differences in conditioning regimens could explain our finding [ 14]. Patients’ comorbidities, mostly unknown in restrospective study, could also have influenced NRM. The 3-year CI of relapse was not different between the three groups.
The lower NRM in MUD 10/10 resulted in both a higher 3-year LFS and OS compared in Haplo but no difference in GRFS. No differences in either OS, LFS, or GRFS were observed between Haplo and MMUD 9/10. Analyzing separately patients with AML and ALL, we found no differences of GRFS in Haplo compared in MUD 10/10 and compared in MMUD 9/10, higher LFS and OS in MUD 10/10 compared in Haplo but no differences between Haplo and MMUD 9/10 in terms of LFS and OS (Additional file 1).
Based on these results, we can assert that patients with acute leukemia in remission showed better outcomes if transplanted from a MUD 10/10. We did not find any significant difference in outcome between MMUD 9/10 and Haplo, suggesting that both can be equally used in the absence of a MUD 10/10 and that other factors, such as urgency of transplant and center expertise should dictate the choice between these two alternative donor sources.
Ongoing and future prospective clinical studies, including transplants from CBU, will ultimately be required to determine the best alternative donor for adult AL patients who lack an HLA-matched sibling one.

Acknowledgements

The authors thank all allogeneic transplantation centers of the EBMT group for reporting to the registry the data included in this analysis. A list of the participating EBMT centers appears in the Additional file 2. We thank Pr J.V. Melo for the critical reading of the manuscript.

Funding

No funding.

Availability of data and materials

Data are entered, managed, and maintained in a central database with Internet access; each EBMT center is represented in this database.

Authors’ contributions

SP, ML, and FC designed the research. SP collected and checked the data and contacted the transplantation centers. SP and ML analyzed the data. SP, ML, FC, MM, AN, and N-CG wrote the paper. FC, MM, AN, AW, K-KS, SS, HH, BD, CC, GZ, and BA provided the data. The results of this study were partially presented as an oral presentation at the EBMT 2014 annual meeting and as a poster presentation at the ASH 2014 meeting. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Jetzt e.Med zum Sonderpreis bestellen!

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Journal of Hematology & Oncology 1/2017 Zur Ausgabe

Neu im Fachgebiet Onkologie

07.05.2021 | DDG-Tagung 2021 | Kongressbericht | Nachrichten

Prävention von aktinischen Keratosen intensivieren

07.05.2021 | DDG-Tagung 2021 | Kongressbericht | Nachrichten

Von Wirkung und Nebenwirkung

07.05.2021 | DDG-Tagung 2021 | Kongressbericht | Nachrichten

Progredienzangst frühzeitig erkennen

07.05.2021 | DDG-Tagung 2021 | Kongressbericht | Nachrichten

Schleimhautmelanom: Neue Therapieoption in Sicht?

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise